Waystar Holding Corp. (WAY)
NEUTRALFundamental
60
Kurs
$24.91
Marktkapitalisierung
$4.82B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Waystar Holding Corp. develops a cloud-based software solution for healthcare payments. Its platform offers financial clearance, patient financial care, claim and payer payment management, denials prevention and recovery, clinical integrity and revenue capture, and analytics and reporting solutions. It primarily serves healthcare industry. The company was founded in 2017 and is headquartered in Lehi, Utah.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$1.21B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$135M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$283M
Gesamtes Eigenkapital
$3.88B
Gesamtverbindlichkeiten
$1.91B
Current Ratio
1.85
Zinsdeckungsgrad
-
Schulden/EBITDA
3.80
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$20.84
Aktueller Kurs
$24.91
Sicherheitsmarge
-19.5%
Innerer-Wert-Spanne
$13.54 - $28.13
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
36.21
ROE
2.9%
P/B-Verhältnis
1.22
P/FCF
19.74
Bruttomarge
-
ROIC
3.9%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
3.9%
WACC
8.4%
ROIC − WACC
-4.6 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (14)
- EPS shows upward trend
- P/FCF 19.74
- P/B Ratio 1.22
- Debt/Equity ratio
- Operating Margin 22.9%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Analyst Consensus 93% Buy
- Earnings Surprise avg 2.5%
- Earnings Quality (OCF/NI) 2.17
- Net Margin Trend 11.2% vs 8.5%
Nicht bestanden (8)
- Price CAGR -17.46%
- ROIC 3.9%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.6%
- Share Dilution 24.9%
- Piotroski F-Score 4/9
Nicht verfügbar (5)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Neue Aktien werden ausgegeben, Eigentum wird verwässert
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Matthew J. Hawkins | CEO & Director | 53 |
| Mr. Steven M. Oreskovich CPA | Advisor | 53 |
| Mr. T. Craig Bridge | Chief Transformation Officer | 52 |
| Ms. Alpana Wegner C.P.A. | Chief Financial Officer | 52 |
| Mr. Edward Akira Parker | Head of Investor Relations | - |
| Mr. Mark Encinger | Vice President of Treasury & Compliance | - |
| Mr. Gregory R. Packer | Chief Legal Officer & Secretary | 45 |
| Kristin Lee | Vice President of Communications | - |
| Mr. Brendan O'Connor | Senior Vice President of Corporate Development & Strategy | - |
| Ms. Kim Wittman | Chief People Officer | 46 |
Prüfungsrisiko
1
Vorstandsrisiko
6
Vergütungsrisiko
4
Aktionärsrechterisiko
8
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for WAY, sourced from Markets Gazette.
- 3/15/2026POSITIVEWaystar Stock Is Down 32% This Past Year, but One Fund Bought Up $11.5 Million Last Quarter
Despite a 32% stock decline over the past year, Waystar Holding Corp. has attracted significant investor interest, with one fund acquiring $11.5 million worth of shares in the last quarter. Waystar, a provider of cloud-based software for healthcare payment and revenue cycle management, appears to be viewed as undervalued by this particular investor. This substantial purchase, against a backdrop of recent poor stock performance, suggests a contrarian bet on the company's long-term prospects and its position within the healthcare technology sector.
via Markets Gazette